Effect of metformin, pioglitazone and vitaminE E in patients with non-alcoholic fatty liver disease

Compare the therapeutic effect of metformin, pioglitazone and vitaminE E in patients with non-alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016010411991N3

Enrollment

Registered

2016-01-22

Start date

2009-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: metformin2 gr daily,orally for12 weeks. Intervention 2: Intervention group: Pioglitazone30 mg dialy, orally for12 weeks. Intervention 3: Intervention group: vitamin

Treatment - Drugs

Intervention group: metformin2 gr daily,orally for12 weeks

Intervention group: Pioglitazone30 mg dialy, orally for12 weeks

Intervention group: vitamin E 800 IU daily, orally for 12 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with non-alcoholic fatty liver disease according to sonographic findings; Having age between 17 to 50 years; Having negative serology of viral hepatitis; Willingness to participate in the study. Exclusion criteriain: having obvious presentations of hepatic diseases; history of jaundice; taking steroids; alcohol drinking; diabetes; pregnancy; hypothyroidism; renal failure.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of fatty liver. Timepoint: before and 12 weeks after the interventions. Method of measurement: according to echogenicity of the liver and its comparison with the adjacent kidney, and also comparison with echogenicity of the spleen, and the view of diaphragm and perivascular region of the intrahepatic vessels.;Serum level of liver function tests (AST, ALT, Alkp). Timepoint: before and 12 weeks after the interventions. Method of measurement: (IU/l) by diagnostic laboratory kits (Pars Azmoon, Iran) and the auto analyzer (Hitachi 902).	—

Measure

Time frame

Severity of fatty liver. Timepoint: before and 12 weeks after the interventions. Method of measurement: according to echogenicity of the liver and its comparison with the adjacent kidney, and also comparison with echogenicity of the spleen, and the view of diaphragm and perivascular region of the intrahepatic vessels.;Serum level of liver function tests (AST, ALT, Alkp). Timepoint: before and 12 weeks after the interventions. Method of measurement: (IU/l) by diagnostic laboratory kits (Pars Azmoon, Iran) and the auto analyzer (Hitachi 902).

—

Secondary

Measure	Time frame
Body mass index(BMI). Timepoint: before and 12 weeks after the interventions. Method of measurement: (Kg/m2).;Insulin resistance index(HOMA-IR). Timepoint: before and 12 weeks after the interventions. Method of measurement: [fasting glucose (mg/dl) × insulin (µU/ml)]/ 405.;Fasting blood sugar. Timepoint: before and 12 weeks after the interventions. Method of measurement: mg/dlby diagnostic laboratory kits (Pars Azmoon, Iran) and the auto analyzer (Hitachi 902).;Serum level of insulin. Timepoint: before and 12 weeks after the interventions. Method of measurement: (µu/ml) by Monobind ELISA kit (Monobind, USA).	—

Measure

Time frame

Body mass index(BMI). Timepoint: before and 12 weeks after the interventions. Method of measurement: (Kg/m2).;Insulin resistance index(HOMA-IR). Timepoint: before and 12 weeks after the interventions. Method of measurement: [fasting glucose (mg/dl) × insulin (µU/ml)]/ 405.;Fasting blood sugar. Timepoint: before and 12 weeks after the interventions. Method of measurement: mg/dlby diagnostic laboratory kits (Pars Azmoon, Iran) and the auto analyzer (Hitachi 902).;Serum level of insulin. Timepoint: before and 12 weeks after the interventions. Method of measurement: (µu/ml) by Monobind ELISA kit (Monobind, USA).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKaroon Shahebrahimi

Kermanshah University of Medical Sciences

kshahebrahimi@gmail.com+98 83 3427 6301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026